Results 21 to 30 of about 85,817,771 (286)

Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11

Frontiers in Immunology, 2020
Cytokines are small signaling proteins that have central roles in inflammation and cell survival. In the half-century since the discovery of the first cytokines, the interferons, over fifty cytokines have been identified. Amongst these is interleukin (IL)
Riley D. Metcalfe, Tracy L. Putoczki, Tracy L. Putoczki, Michael D. W. Griffin   +3 more
doaj   +1 more source

The interleukin-6/interleukin-6-receptorsystem is activated in donor hearts

Journal of the American College of Cardiology, 2002
To assess the potential of the donor heart to respond to interleukin-6 (IL6), the present study investigated the expression of IL6 receptor components in the myocardium of donor hearts before transplantation.Donor heart dysfunction early after transplantation has been associated with the cytokine storm after donor brain death. Proinflammatory cytokines
Plenz, Gabriele, Eschert, Heike, Erren, Michael, Wichter, Thomas, Böhm, Michael, Flesch, Markus, Scheld, Hans H., Deng, Mario C.   +7 more
openaire   +2 more sources

Serum levels of interleukin-6 and interleukin-8 as diagnostic markers of acute pyelonephritis in children [PDF]

Korean Journal of Pediatrics, 2013
PurposeEarly diagnosis and treatment of acute pyelonephritis in children is of special importance in order to prevent serious complications. This study was conducted to determine the diagnostic value of serum interleukin (IL)-6 and IL-8 in children with ...
Abolfazl Mahyar, Parviz Ayazi, Mohammad Reza Maleki, Mohammad Mahdi Daneshi-Kohan, Hamid Reza Sarokhani, Hassan Jahani Hashemi, Mousa Talebi-Bakhshayesh   +6 more
doaj   +1 more source

Genetic partitioning of interleukin-6 signalling in mice dissociates Stat3 from Smad3-mediated lung fibrosis [PDF]

, 2012
Idiopathic pulmonary fibrosis (IPF) is a fatal disease that is unresponsive to current therapies and characterized by excessive collagen deposition and subsequent fibrosis.
Bozinovski, S, O'Donoghue, R.J.J., Prêle, C.M., Ernst, M.R., Anderson, GP, Vlahos, R., Knight, DA, McKenzie, B.S., Wang, B, Jarnicki, AG, Prêle, CM, Laurent, GJ, McAnulty, R.J., Thiem, S, Lau, HL, Vlahos, R, Zhu, H.J., Richards, CD, Mutsaers, SE, Ernst, MR, Stumbles, P.A., Laurent, G.J., Knight, D.A., Thiem, S., Jarnicki, A.G., Lau, H.L., O'Donoghue, RJJ, McAnulty, RJ, Stumbles, P, Richards, C.D., Anderson, G.P., McKenzie, BS, Rose-John, S, Mutsaers, S.E., Zhu, HJ, Wang, B., Jones, J., Rose-John, S., Jones, J, Bozinovski, S.   +39 more
core   +1 more source

Association of Interleukin 6 Gene Variant and Interleukin 6 level in Children with Congenital Heart Diseases: Single Center Case – Control Study [PDF]

Pediatric Sciences Journal (Egypt)
Background: Etiology of most congenital heart diseases (CHDs) is multifactorial, they include genetic and environmental factors. Interleukin-6 (IL-6) gene variant rs1800795 was reported to be associated with CHD among Chinese children.
Hala Ashraf, Noha Bagdadi, Ahmed Said Behairy, Mahmoud Osman , Heba H. Zeid   +4 more
doaj   +1 more source

A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects.

, 2007
Interleukin-6 (IL-6) is a key inflammatory cytokine, signalling to most tissues by binding to a soluble IL-6 receptor (sIL-6r), making a complex with gp130.
A Murray, Henley, W, Bandinelli, S, S Rafiq, Rafiq, S, Weedon, MN, Guralnik, JM, Hurst, A, A-M Corsi, Ferrucci, L, K Stevens, S Bandinelli, M N Weedon, Corsi, A-M, L Ferrucci, Murray, A, D Melzer, W Henley, T M Frayling, J M Guralnik, A Hurst, Stevens, K, Melzer, D, Frayling, TM   +23 more
core   +1 more source

Evidence‐Based Clinical Practice Guidelines for the Management of Pediatric Febrile Neutropenia: Resource‐Sensitive Recommendations for the Asian Continent

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Febrile neutropenia (FN) is a frequent and serious complication in children receiving cancer therapy. Standardizing FN management across Asia is challenging due to variable healthcare infrastructure, diagnostic capacity, and infection patterns; however, it could improve resource use and patient outcomes.
Joliza Patricia Cañeba, Shweta Bansal, Tea Reljic, Allyne Montecillo‐Aguelo, Hamidah Alias, Farrah Amaranto, Maria Stella Aquino‐Calingasan, Bambang Ardianto, Eggi Arguni, Sally Blair, Thi Tam Dang, Maria Beatriz Gepte, Samanmalee Gunasekara, Andini Handayani, Miriam Kimpo, Catherine G. Lam, Nawachai Lertvivatpong, Sergio Licona, Ana Loseo, Ratha Mlis, Vivian Moreno Berrio, Nguyen Hoai Anh, Anna Lisa Ong‐Lim, Ha Thu Pham, Krishna Sagar Sharma, Bun Sereyleak, Sally Jane G. Velasco‐Aro, Su Yadana, Ambuj Kumar, Sheena Mukkada   +29 more
wiley   +1 more source

Targeting IL-6 Receptor Signaling with Satralizumab in Thyroid Eye Disease: Design of the Phase 3 SatraGO-1 and SatraGO-2 Trials

Ophthalmology and Therapy
Introduction Thyroid eye disease (TED) is a rare, autoimmune, orbital inflammatory disorder that is disfiguring, debilitating, and potentially sight-threatening.
Daniel Ezra, Atif Collins, Zdenka Haskova, Thomas Kuenzel, Hiroaki Ida, Miriam Triyatni, Christopher Brittain, Oluwatobi Idowu   +7 more
doaj   +1 more source

Microbiome‐blood–brain barrier interactions in aging — mechanisms and therapeutic potential

FEBS Letters, EarlyView.
Aging reshapes the gut microbiome (↓SCFA‐producing commensals; ↑pro‐inflammatory outputs), shifting circulating metabolites (↓SCFAs; ↑LPS, ↑TMAO, ↑PAA) that act at the BBB to increase nonspecific transcytosis, alter transport, and promote astrocyte reactivity, heightening brain vulnerability.
Daniel Cuervo‐Zanatta, Hari Baskar Balasubramanian, Amir Pasokh, Marietta Zille   +3 more
wiley   +1 more source

Criteria for the optimal use of interleukin-6 receptor blockers in patients with COVID-19

Терапевтический архив, 2021
Aim. To determine the criteria for the optimal use of IL-6 receptor blockers in patients with COVID-19 community-acquired pneumonia based on predictors of adverse outcomes. Materials and methods.
Tatyana S. Kruglova, Darya S. Fomina, Nataliya G. Poteshkina, Nadija F. Frolova, Irina P. Beloglazova, Zinaida Yu. Mutovina, Inna V. Samsonova, Elena A. Kovalevskaja, Alena I. Zagrebneva, Sofya A. Serdotetckova, Anton A. Chernov, Maryana A. Lysenko   +11 more
doaj   +1 more source